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Abstract
Multiple body site screening and pre-emptive isolation of patients at risk for methicillin-resistant Staphylococcus aureus (MRSA) carriage
are considered essential for control of nosocomial spread. The relative importance of extranasal screening when using rapid diagnostic
testing (RDT) is unknown. Using data from a multicentre study evaluating BD GeneOhmTM MRSA PCR (IDI), Xpert MRSA (GeneXpert)
and chromogenic agar, added to conventional cultures, we determined cost-effectiveness assuming isolation measures would have been
based on RDT results of different hypothetical screening regimes. Costs per isolation day avoided were calculated for regimes with sin-
gle or less extensive multiple site RDT, regimes without conventional back-up cultures and when PCR would have been performed with
pooling of swabs. Among 1764 patients at risk, MRSA prevalence was 3.3% (n = 59). In all scenarios the negative predictive value is
above 98.4%. With back-up cultures of all sites as a reference, the costs per isolation day avoided were €15.19, €30.83 and €45.37 with
‘nares only’ screening using chromogenic agar, IDI and GeneXpert, respectively, as compared with €19.95, €95.77 and €125.43 per isola-
tion day avoided when all body sites had been screened. Without back-up cultures costs per isolation day avoided using chromogenic
agar would range from €9.24 to €76.18 when costs per false-negative RDT range from €5000 up to €50 000; costs for molecular
screening methods would be higher in all scenarios evaluated. In conclusion, in a low endemic setting chromogenic agar screening added
to multiple site conventional cultures is the most cost-effective MRSA screening strategy.
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Introduction
Nosocomial infections caused by antibiotic-resistant bacteria,
such as methicillin-resistant Staphylococcus aureus (MRSA),
are a global healthcare problem, resulting in increased mor-
tality and high healthcare costs [1–4]. There is considerable
geographical variation in the prevalence of nosocomial MRSA
infections. In countries with successful nationwide infection
control policies for MRSA, such as in Scandinavian countries
and the Netherlands, reported MRSA rates among S. aureus
bloodstream infections are still around 1% [5]. In countries
without such infection control programmes MRSA preva-
lence has been reported to be as high as over 55% [6,7].
Screening and pre-emptive isolation of patients at high-risk
for MRSA carriage is considered an essential part of the
search and destroy policy. The screening strategy requires
sampling of multiple body sites. In the Netherlands, swabs of
the anterior nares, throat, perineum and, if present, wounds,
catheter insertion sites and sputum are recommended for
MRSA screening, according to a national protocol [8]. Until
recently screening methods, using conventional microbiologi-
cal culture techniques, had a diagnostic delay of 3–5 days,
during which screened but uncolonized patients remained
pre-emptively isolated. Rapid diagnostic testing (RDT), using
molecular methods or chromogenic agars, can offer results
within 24 h (or even faster), albeit at extra costs [9]. Natu-
rally, sensitivity of MRSA screening increases with the num-
ber of body sites tested, but there is no consensus on the
choice of anatomical sites to be sampled and the relative
importance of extranasal screening is unknown [10–14]. We,
therefore, determined costs and effects of different MRSA
screening regimes using RDT, by varying the number of body
sites tested and whether or not conventional back-up cul-
tures were included.
Materials and Methods
Study design and setting
A prospective multicentre study was performed in 14 Dutch
hospitals (ﬁve university hospitals, nine teaching hospitals)
between December 2005 and June 2008. All patients at risk
of MRSA colonization and fulﬁlling the criteria for pre-emp-
tive isolation were eligible. In addition to conventional cul-
tures, RDT of MRSA was performed directly on patient
material with decisions on isolation measures based on PCR
results. Two real-time PCR assays were subsequently evalu-
ated: BD GeneOhmTM MRSA PCR (BD Diagnostics, San
Diego, CA USA) between December 2005 and May 2007
(‘IDI study’), and Xpert MRSA assay (Cepheid, Sunnyvale,
CA, USA) between April 2007 and June 2008 (‘GeneXpert
study’). Within the framework of the IDI study, a nested
prospective cohort study was performed in 10 of the 14
hospitals, between February 2006 and May 2007, to deter-
mine effects of screening with a chromogenic agar plate
(MRSA-ID, bioMe´rieux, Marcy-l’Etoile, France) (‘chromogenic
study’). However, the results of chromogenic agar testing
were not used to change isolation measures, as these deci-
sions were always based on BD GeneOhmTM MRSA PCR
results. The institutional review board was informed but
approval was not needed for this study. The effects of RDT
on pre-emptive isolation duration and costs have been pub-
lished elsewhere [9].
Microbiological analyses
Swabs from the anterior nares, throat, perineum and, if pres-
ent, wounds, catheter insertion sites, sputum and urine sam-
ples (in the case of an indwelling urinary catheter) were
obtained directly after meeting eligibility criteria. Swabs for
PCR were taken ﬁrst; subsequently, swabs were taken for
conventional and chromogenic culture. Specimens for conven-
tional microbiological cultures were processed according to
the guidelines of the Dutch Society of Medical Microbiology
[15]. After inoculation of agar plates for conventional cultures,
specimens were plated directly on the selective chromogenic
agar MRSA-ID, and interpreted after 18–24 h. Details of the
molecular procedures are published elsewhere [9].
On a patient level, test results were considered positive if
at least one RDT result was positive and were considered
negative if the nasal swab was negative (and other sites were
negative or non-conclusive). In the case of a non-conclusive
PCR result of the nasal swab, the overall test result for that
patient was considered non-conclusive; these patients were
not taken into account for determination of test characteris-
tics. Test characteristics for less extensive screening regimes
were calculated regarding multiple site testing with conven-
tional cultures (including broth enrichment) as the reference
standard.
Study endpoint and cost analyses
The primary endpoint of the current analysis was the cost
per isolation day avoided with less extensive RDT screening
regimes (i.e. fewer body sites screened) as compared with
the current Dutch search and destroy policy. We deter-
mined cost-effectiveness assuming isolation measures would
have been based on RDT using screening regimes with single
or less extensive multiple site testing, using screening
regimes without conventional back-up cultures and when
screening with PCR would have been performed with pool-
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ing of swabs. Pre-emptive isolation days avoided when using
less extensive screening regimes were calculated upon the
hypothetical scenario that these screening regimes had been
used in decision making on termination of isolation. The
effect of pooling swabs is calculated for the scenario that
all unresolved PCR results would have resulted in an
unresolved pool (worst case scenario) and the scenario with-
out unresolved results with pooling (best case scenario).
Pooling of specimens per se was assumed not to inﬂuence
sensitivity or speciﬁcity of the test.
Costs for RDT included costs for MRSA PCR or chromo-
genic agar and costs because of false-negative RDT results.
Costs of one false-negative PCR results were estimated to be
€1441.13 for the scenarios with back-up cultures (mean costs
of contact screenings because of ten false-negative MRSA
PCR results during the clinical study) [9]. Back-up cultures will
guarantee that false-negative RDT results will be detected
within 2–4 days after discontinuation of isolation measures.
Additional costs because of false-negative RDT results with-
out back-up cultures are unknown, but will depend on the
rate of MRSA transmission and its possible consequences
(e.g. outbreak, infections), and were, therefore, varied from
€0 to €50 000. The number of avoided isolation days for the
scenarios with back-up cultures are calculated and remained
constant for the scenarios without back-up cultures. The addi-
tional isolation days between the day of the back-up culture
result and the day of discharge for patients with false-positive
MRSA PCR results were not included.
Results
Patient population
One thousand seven hundred and sixty-four patients were
included in the study. The prevalence of MRSA carriage in
high-risk patients, based upon conventional microbiological
cultures, was 3.3% (n = 59 patients). Baseline characteristics
of these patients using multiple site MRSA screening as per-
formed in the prospective multicentre study are summarized
in Table 1. Costs of screening tests and false-negative RDT
results are presented in Table 2.
Test characteristics
Using the results of conventional cultures as reference, sensi-
tivity, speciﬁcity and positive and negative predictive values
for detecting MRSA on a patient level were calculated for
RDT screening regimes including ‘nares only’, ‘nares and
throat’, ‘nares and perineum’, ‘nares and skin’ and all sites
(Table 3). With less extensive screening regimes sensitivity
decreases and speciﬁcity increases, which would avoid more
isolation days. The percentages of avoided isolation days with
single site testing of the nose, as compared with multiple site
testing, would be 2.8%, 4.9% and 4.2% higher using BD
GeneOhmTM MRSA PCR, Xpert MRSA assay and MRSA-ID,
respectively. In all scenarios the negative predictive value is
above 98.4%.
Costs per isolation day avoided with and without conven-
tional back-up cultures
As compared with screening ‘nares only’, multiple site
screening prevented four and six false-negative cases using
BD GeneOhmTM MRSA PCR (4/853, 0.5%) and Xpert MRSA
TABLE 1. Baseline characteristics of multicentre study with
multiple site testing [9]
IDI
study
GeneXpert
study
Chromogenic
study
No. of patients 853 911 428
MRSA carriage (%) 27/853 (3.2) 32/911 (3.5) 13/428 (3.0)
No. of RDTs 3113 3045 1485
No. of back-up cultures 3147 3345 1513
No. of false-negative
RDT results
4 8 1
No. of avoided isolation
days with RDT
1888 1782 672
TABLE 2. Cost of MRSA screening tests and false negative
RDT results [9]
Resource unit Cost/unit (€)
BD GeneOhmTM MRSA PCR 56.22
Xpert MRSA assay 69.62
Chromogenic agar MRSA-ID 8.06
Conventional culture 7.11
Total costs per false-negative RDT result 1441.13
TABLE 3. Test characteristics of different RDT MRSA
screening regimes
Sites screened with RDT
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Nose
BD GeneOhmTM MRSA PCR 69.2 98.4 58.1 99.0
Xpert MRSA assay 56.3 97.3 43.9 98.4
Chromogenic agar 61.5 98.8 61.5 98.8
Nose and throat
BD GeneOhmTM MRSA PCR 70.4 97.7 50.0 99.0
Xpert MRSA assay 65.6 96.1 38.2 98.7
Chromogenic agar 78.6 97.8 55.0 99.3
Nose and perineum
BD GeneOhmTM MRSA PCR 81.5 97.7 53.7 99.4
Xpert MRSA assay 68.8 95.5 36.1 98.8
Chromogenic agar 64.3 97.8 50.0 98.9
Nose and skin lesionsa
BD GeneOhmTM MRSA PCR 73.1 97.9 52.8 99.1
Xpert MRSA assay 64.5 97.2 45.5 98.7
Chromogenic agar 76.9 97.8 52.6 99.3
All sites
BD GeneOhmTM MRSA PCR 85.2 96.5 44.2 99.5
Xpert MRSA assay 75.0 94.5 33.3 99.1
Chromogenic agar 85.7 96.6 46.2 99.5
PPV, positive predictive value; NPV, negative predictive value.
aIncluding wounds, i.v. lines, etc.
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assay (6/911, 0.7%), respectively, at the (average) additional
costs of €148.55 and €161.78 per patient. The costs for one
prevented false-negative case with multiple site screening
are, respectively, €31 680 and €24 564 when using BD Gene-
OhmTM MRSA PCR and Xpert MRSA assay. Chromogenic
agar testing of multiple sites would have prevented four
false-negative results (4/428, 0.9%), as compared with screen-
ing ‘nares only’ at the additional costs of €19.93 per patient.
Mean costs for a false-negative RDT result were calculated
to be €1441.13 [9]. Costs per isolation day avoided with less
extensive screening regimes, but with conventional back-up
cultures of all sites, are presented in Table 4.
If we assume that an unresolved PCR result from a single
body site will also lead to an unresolved PCR result from
pooled samples, then 13.1% and 15.5% of the patients would
have remained in isolation when swabs were pooled for the
IDI and GeneXpert test, respectively. The costs per isolation
day avoided would have been €30.30 and €47.66 for BD
GeneOhmTM MRSA PCR and Xpert MRSA assay in the IDI
and GeneXpert study, respectively. If pooling of swabs would
never reveal unresolved results, costs per isolation day
avoided would be €27.57 and €41.36 for the BD Gene-
OhmTM MRSA PCR and Xpert MRSA assay, respectively.
Additional costs because of false-negative RDT results
without back-up cultures are unknown and were therefore
varied from €0 up to €50 000 per case. In this scenario,
screening multiple sites with chromogenic agar is most bene-
ﬁcial (Fig. 1). ‘Nares only’ screening is favourable over multi-
ple site screening as long as average costs per false-negative
RDT result remain below €30 000 when using BD Gene-
OhmTM MRSA PCR and below €25 000 when using the
Xpert MRSA assay (Fig. 2).
TABLE 4. Costs per isolation day avoided for the scenario
with conventional back-up cultures of all sites
Sites screened with RDT
Nose
Nose
and throat All sites
BD GeneOhmTM
MRSA PCR
€30.83 €56.14 €95.77
Xpert MRSA assay €45.37 €79.12 €125.43
Chromogenic agar €15.19 €16.29 €19.95
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FIG. 1. Costs per isolation day avoided for multiple site testing
without conventional back-up cultures. RDT, rapid diagnostic testing.
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(b) GeneXpert study
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(c) Chromogenic study
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FIG. 2. Costs per isolation day avoided for RDT testing without
back-up cultures using BD GeneOhmTM MRSA PCR (a), Xpert
MRSA assay (b) and chromogenic agar (c). RDT, rapid diagnostic
testing.
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Discussion
Although multiple site screening strategies will be more
sensitive than ‘nares only’ screening, the latter strategy
appeared to be most cost-effective when using RDT in a
multicentre study performed in low endemic settings. With
conventional back-up cultures of all sites as a reference, the
costs per isolation day avoided were €15.19, €30.83 and
€45.37 with ‘nares only’ screening using chromogenic agar,
BD GeneOhmTM MRSA PCR and Xpert MRSA assay, respec-
tively, as compared with €19.95, €95.77 and €125.43 per
isolation day avoided when all body sites had been screened
(as recommended) with these three tests, respectively.
Without conventional back-up cultures to adjust for any
false-negative RDT results, predicted costs per isolation day
avoided using chromogenic agar would range from €9.24 to
€76.18 when costs per false-negative RDT range from €5000
up to €50 000, and (with current pricing levels) costs for
molecular screening methods would be higher in all scenarios
evaluated.
The anterior nares are considered the most important
screening site for colonization with S. aureus, both methicil-
lin-sensitive (MSSA) and MRSA [16–18], although some stud-
ies suggest that the throat is the most common colonization
site [14,19]. Screening extranasal sites in addition to the
nares increases the sensitivity to detect MRSA carriers, with
2–34% of MRSA carriers being detected through extranasal
screening only [10,12,13]. With conventional cultures and
broth enrichment as reference, sensitivities of multiple site
RDT were suboptimal, being 85.2%, 75.0% and 85.7% for BD
GeneOhmTM MRSA PCR, Xpert MRSA assay and chromo-
genic agar, respectively. Our ﬁndings now demonstrate that
in such a setting (with back-up cultures being performed any-
way) ‘nares only’ screening with RDT is more beneﬁcial than
molecular RDT of samples obtained from multiple body sites,
increasing the costs per isolation day avoided, with €64.94
and €80.06 for BD GeneOhmTM MRSA PCR and Xpert
MRSA assay, respectively. For chromogenic agar screening
the additional costs for multiple site screening are limited.
Cost-effectiveness of a control policy based on screening
and pre-emptive isolation is determined by the costs of the
screening method and the savings generated by reductions in
isolation days and transmission events (leading to further
screening, isolation and infections). Although RDT of MRSA
with molecular methods has been shown to reduce MRSA
bloodstream infections, its use is not associated with a
decrease in MRSA acquisition rates or surgical-site infections
when compared with culture screening [20]. Also, cost-effec-
tiveness of MRSA PCR remains to be determined [9,21–23].
In a low endemic setting, chromogenic agar screening is
probably cost-effective but molecular screening is not [9].
Based on our experience in hospitals with low levels of
MRSA, it can be expected that also in countries with ende-
mic MRSA, multiple body site screening with chromogenic
agar will have a sensitivity that is comparable to that of
molecular RDT, but at lower costs. Naturally, longer turn-
around times (about 32 h for chromogenic agar as compared
with 14–22 h for molecular methods) [9,24–29] are an
important drawback of chromogenic agar testing, but with
current pricing of molecular tests, it is uncertain whether
the shorter turn-around time will outweigh the higher costs.
Pooling of patient samples in the laboratory may increase
sensitivity, as compared with single site testing, while avoid-
ing expenses of multiple testing. Depending on whether we
incorporate inhibition of test procedures, calculated costs
per avoided isolation day would have ranged between €27.57
and €30.30 for BD GeneOhmTM MRSA PCR and between
€41.36 and €47.66 for the Xpert MRSA assay, which is con-
siderably lower than €95.77 and €125.43, when all sites were
tested separately. Yet, pooling samples may reduce sensitiv-
ity, which has been demonstrated for conventional cultures
[30], BD GeneOhmTM MRSA PCR [31] and Xpert MRSA
assay [32]. Furthermore, pooling may increase the rate of
inhibition for the BD GeneOhmTM MRSA PCR and for the
Xpert MRSA assay [32,33], yet technical adjustments of the
procedure (e.g. dilution of the sample or an extra heating
step) have been shown to reduce this effect [31–33].
Our study has several limitations, such as the hypotheti-
cal nature of the consequences of the different screening
regimes. In a scenario without back-up cultures, false-posi-
tive RDT results would increase the number of isolation
days because without back-up cultures isolation will be con-
tinued until discharge. The additional isolation days between
the day of the back-up culture result and the day of dis-
charge were not taken into account in our analyses. How-
ever, as the number of false-positive cases will decrease
with less extensive screening regimes and because speciﬁcity
was already very high, this omission did not change our
conclusions. Another limitation is that our study was per-
formed in hospitals in the Netherlands, and may not be
fully generalizable to hospitals with higher MRSA prevalence
levels in other countries. Further research in countries with
a high MRSA prevalence is needed to determine this. In
addition, colonization patterns of healthcare-acquired MRSA
may well differ from those of community-acquired MRSA
(CA-MRSA) [34], and the relative importance of extranasal
screening might be different for CA-MRSA. Human-derived
CA-MRSA isolates are only sporadically encountered in
Dutch hospitals.
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Our results demonstrate that in a low endemic setting
chromogenic agar screening added to conventional microbio-
logical cultures of samples from multiple body sites as back
up is the most cost-effective MRSA screening strategy. When
more expensive molecular methods (with shorter turn-
around times) are to be used, ‘nares only’ screening with
PCR is recommended when performed in addition to con-
ventional microbiological cultures of samples from multiple
body sites as back up.
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